ResonanceDx, Inc. is a Point-of-Care diagnostic device startup company. Our novel, flexible testing platform can provide rapid results to support immediate clinical decision-making.

The ResonanceDx

platform uses highly sensitive Bulk Acoustic Resonance Sensing (BARS*) to rapidly measure binding of antigens to antibodies in real time with no sample preparation, reagents, or lasers.

*US Patents 9,473,106 and 8,810,108

US Patent pending 14/759,078 and others

Wafer of ResonanceDx Sensors

Silicon wafer fabrication of sensor arrays makes scaling of manufacturing inexpensive

Tech-fig-8-22-20.jpg

The technology detects shifts in resonant frequencies of antibodies bound to piezoelectric resonators.

News:

ResonanceDx, Inc recently placed in the Final Five Finalists of the 2021 Cade Prize.

Carlos Moreno interviewed by the Radio Cade Podcast.

Carlos Moreno interviewed by CEOCFO Magazine.

Questions?

© copyright 2020, ResonanceDxTM, Inc. all rights reserved.